Elicera Therapeutics will participate in upcoming industry and investor conferences during the fall
Gothenburg, September 3, 2024 – Elicera Therapeutics AB (publ), a clinical stage cell and gene therapy company developing next generation cancer treatments based on CAR T-cell therapies and oncolytic viruses, armed with its proprietary and commercially available technology platform iTANK, announces that the company will participate in the following industry and investor conferences during the fall of 2024:
ISCT Europe 2024 Regional Meeting, September 4
Elicera Therapeutics will participate in the annual conference organized by the scientific network International Society for Gene & Cell Therapy. For more information: https://www.isctglobal.org/iscteu2024/home
CICON24 (Eighth International Cancer Immunotherapy Conference), September 8
Elicera Therapeutics' co-founder and CSO, Magnus Essand, has been invited to present iTANK and the company’s development of CAR T-cell therapies. For more information: www.cancerimmunotherapyconference.org
Biostock Investor Meeting, September 12
Elicera Therapeutics' CEO, Jamal El-Mosleh, will present the company at an investor meeting organized by Biostock. For more information: https://www.biostock.se/investing-in-life-science/
NLSDays 2024, September 18–19
Elicera Therapeutics will participate in Nordic Life Science Days, the Nordic region's largest business conference in life science. For more information: www.nlsdays.com/about-the-event
Miltenyi Cell and Gene Therapy Summit 2024, October 8
Elicera Therapeutics' co-founder and CSO, Magnus Essand, has been invited to present iTANK and the company’s development of CAR T-cell therapies. For more information: www.miltenyibiotec.com/UN-en/about-us/conferences-and-events/miltenyi-biotec-s-cell-and-gene-therapy-days.html
BIO-EUROPE, November 4
Elicera Therapeutics will participate in Europe’s largest business conference in life science. For more information: www.informaconnect.com/bioeurope
Biostock Summit, November 19
Elicera Therapeutics will present at the annual investor meeting organized by Biostock. The company’s presentation will be published on their website.
For further information please contact:
Jamal El-Mosleh, CEO, Elicera Therapeutics AB
Phone: +46 (0) 703 31 90 51
jamal.elmosleh@elicera.com
Certified Advisor
Mangold Fondkommission AB
About Elicera Therapeutics AB
Elicera Therapeutics AB is a clinical stage cell and gene therapy company that develops next generation immune-oncology treatments based on iTANK-armed oncolytic viruses and CAR T-cells. The work is based on high-profile long-standing research conducted by Professor Magnus Essand’s research group at Uppsala University and has resulted in the development of four drug candidates, including two CAR T-cells and two oncolytic viruses. The iTANK-technology platform can be used to arm any CAR T-cell therapy in development and activate killer T-cells against cancer. The company addresses an international billion-dollar market in cell therapy development by offering out-licensing of iTANK to CAR T-cell players in the pharmaceutical industry. The company’s share (ELIC) is traded on Nasdaq First North Growth Market. For more information, please visit www.elicera.com